Beclomethasone dipropionate (Ciplanaze)
Beclomethasone dipropionate
Forrester Pharma (Pty) Ltd
Every registration of this product has been cancelled.
Registration
- Applicant
- Forrester Pharma (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Ciplanaze EACH 10,0 ml SUSPENSION CONTAINS BECLOMETHASONE DIPROPIONATE 12,4 mg | Not listed | 34007134/21.5.1/0071 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Beclomethasone dipropionate
- except when intended for inhalation or nasal administration.
Consolidated Schedules 06 July 2026, line 5441
S3: Beclomethasone dipropionate
- when intended for inhalation or nasal administration, except when intended for nasal administration as an aqueous spray, other than by pressurised aerosol, and indicated for the treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to
- a maximum dose of 100 micrograms per nostril and a maximum daily dose of 200 micrograms of per nostril and
- a maximum pack size of 200 doses. (S2, S4)
Consolidated Schedules 06 July 2026, lines 3170 to 3177
S2: Beclomethasone dipropionate
- when intended for nasal administration as an aqueous spray, other than by pressurised aerosol, and indicated for the treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to
- a maximum dose of 100 micrograms per nostril and a maximum daily dose of 200 micrograms of per nostril and
- a maximum pack size of 200 doses. (S3, S4)
Consolidated Schedules 06 July 2026, lines 1647 to 1654
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
[2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-Chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
Drag to rotate. Structure from PubChem CID 21700.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.